Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 12;13:1020580. doi: 10.3389/fimmu.2022.1020580

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Muri, Schubart, Thorburn, Zamurovic, Holbro, Kammüller, Pluschke and Ispasanie

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparative analysis of the effect of complement inhibitors on the survival of Hib in pre- and post-vaccination sera. Survival data for all subject/Hib isolate combinations were cumulated (three technical replicates for each combination). The horizontal dotted line represents 50% survival of bacteria after 60 min incubation. Shown are results for the highest concentrations of complement inhibitors tested (25 µM for the fB inhibitor iptacopan and the fD inhibitor CMS487, 100 µg/mL for the C3 inhibitor CP-40, the anti-C5 mAb tesidolumab and the anti-MASP-2 mAb). CI, confidence interval.